The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Syndax Pharmaceuticals Inc shares valued at $581,040 were purchased by DENNIS G PODLESAK on Aug 14 ’25. At $13.45 per share, DENNIS G PODLESAK acquired 43,200 shares.
Also, Goldan Keith A. sold 1,296 shares, netting a total of over 12,033 in proceeds. Following the sale of shares at $9.29 each, the insider now holds 92,450 shares.
Before that, Metzger Michael A had sold 7,534 shares from its account. In a trade valued at $69,953, the Chief Executive Officer traded Syndax Pharmaceuticals Inc shares for $9.29 each. Upon closing the transaction, the insider’s holdings decreased to 7,534 shares, worth approximately $4.4 million.
As published in a research note from BTIG Research on August 05, 2025, Syndax Pharmaceuticals Inc [SNDX] has been retained to a Buy and the price target has been revised to $56. Analysts at Goldman started covering the stock with ‘”a Buy”‘ outlook in a report released in early July. As of October 24, 2024, UBS has initiated its “Buy” rating for SNDX. Earlier on June 28, 2024, Jefferies initiated its rating. Their recommendation was “a Buy” for SNDX stock.
Analyzing SNDX Stock Performance
On last trading session, Syndax Pharmaceuticals Inc [NASDAQ: SNDX] rose 9.52% to $14.73. The stock’s lowest price that day was $13.26, but it reached a high of $14.81 in the same session. During the last five days, there has been a surge of approximately 15.80%. Over the course of the year, Syndax Pharmaceuticals Inc shares have dropped approximately -25.00%. Shares of the company reached a 52-week high of $16.95 on 02/21/25 and a 52-week low of $8.58 on 05/15/25.
Support And Resistance Levels for Syndax Pharmaceuticals Inc (SNDX)
According to the 24-hour chart, there is a support level at 13.72, which, if violated, would cause prices to drop to 12.72. In the upper region, resistance lies at 15.27. The next price resistance is at 15.82. RSI (Relative Strength Index) is 79.43 on the 14-day chart, showing overbought technical sentiment.
Is Syndax Pharmaceuticals Inc subject to short interest?
Stocks of Syndax Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-31 jumping by 34893.0 shares to 23.9 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 23.87 million shares. A jump of 0.15% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 13.24 of the overall float, the days-to-cover ratio (short ratio) jumped to 13.24.
Which companies own the most shares of Syndax Pharmaceuticals Inc (SNDX)?
In terms of Syndax Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 26.5 in the next 12 months, up nearly 97.03% from the previous closing price of $13.45. Analysts anticipate Syndax Pharmaceuticals Inc stock to reach 35 by 2025, with the lowest price target being 18. In spite of this, 4 analysts ranked Syndax Pharmaceuticals Inc stock as Buy at the end of 2025. On January 31, 2024, Scotiabank assigned a price target of “a Sector perform” to the stock and downgraded coverage with a $23.
